Nalaganje...

Rituximab efficiently depletes increased CD20 expressing T cells in multiple sclerosis patients()

In multiple sclerosis (MS()) B cell depleting therapy using monoclonal anti-CD20 antibodies, including rituximab (RTX) and ocrelizumab (OCR), effectively reduces disease activity. Based on indirect evidence, it is generally believed that elimination of the antigen presenting capabilities and antigen...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Palanichamy, Arumugam, Jahn, Sarah, Nickles, Dorothee, Derstine, Mia, Abounasr, Aya, Hauser, Stephen L., Baranzini, Sergio E., Leppert, David, von Büdingen, H.-Christian
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4082756/
https://ncbi.nlm.nih.gov/pubmed/24928997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1400118
Oznake: Označite
Brez oznak, prvi označite!